All articles tagged with #cbd
A scientific review suggests that CBD, a non-intoxicating compound in marijuana, shows significant potential as an anti-tumor agent across various cancers, including aggressive types like glioblastoma, by disrupting multiple cancer pathways. However, challenges such as poor absorption and delivery methods remain, and further clinical research is needed to confirm its efficacy in patients.
A review led by OHSU found that some cannabis products, particularly those containing THC, can slightly reduce chronic pain, similar to traditional painkillers like ibuprofen, but the effect is small and may come with side effects. CBD alone showed little to no impact on pain, and the findings suggest caution in using cannabis for pain management, emphasizing the need for further research and personalized medical advice.
In North Carolina, marijuana remains illegal, but hemp products with less than 0.3% THC are legal, though a new federal law set to take effect in 2026 may ban these products due to increased THC limits, threatening the state's multi-billion-dollar hemp industry and raising public safety concerns. The debate involves federal and state regulations, industry impacts, and public health considerations.
A review of clinical trials indicates that high-THC cannabis products may offer modest short-term relief for chronic pain, especially nerve pain, but they also increase the risk of side effects. CBD-only products do not appear to provide significant pain relief. The findings highlight the need for more research on long-term effects and safety.
President Donald Trump signed an executive order to expand access to marijuana and CBD, citing their medical benefits, as part of a broader move to ease restrictions despite not decriminalizing the substances.
President Trump signed an executive order to reclassify cannabis from Schedule I to Schedule III, aiming to expand research and access, while maintaining federal illegality; the move has received mixed reactions from lawmakers and the public.
Laboratory studies suggest that a combination of cannabis-derived compounds THC and CBD can inhibit the growth and spread of ovarian cancer cells with minimal effects on healthy cells, offering potential for new, less toxic treatments, though further research is needed to confirm efficacy and safety in vivo.
President Trump is expected to sign an executive order reclassifying cannabis as a Schedule III drug, which could expand access to CBD products, include Medicare coverage for seniors, and significantly impact the cannabis industry, research, and investments, despite ongoing scientific and regulatory debates.
A last-minute provision in a federal spending bill aiming to restrict hemp-derived products like CBD and THC has caused disquiet among Republicans, especially in hemp-producing Kentucky, threatening the bill's passage and the end of the government shutdown. The provision, which bans products with more than 0.4 mg of THC per container, is opposed by some lawmakers and industry leaders who argue it could lead to an unregulated market and harm consumers. The bill is expected to pass with some opposition, and advocates hope to replace the ban with more thoughtful regulations.
Scientists have developed a nano-formulation called CBD-IN that effectively delivers CBD to the brain in mice, providing pain relief without side effects and without relying on traditional cannabinoid receptors, potentially opening new avenues for treating chronic pain and neurological disorders.
The cannabis industry is optimistic about potential federal reforms under Trump, including possible reclassification of marijuana and regulation of hemp-derived products, which has already sparked a rally in cannabis stocks. Key developments include Trump's supportive statements on CBD and hemp regulation, though Republican lawmakers are pushing back on safety concerns. The sector's future growth hinges on regulatory clarity and policy changes, with the market showing signs of a potential turnaround.
Research suggests that certain components of marijuana, particularly CBD with low doses of THC, may help some individuals fall asleep faster and stay asleep longer, but effects vary and higher THC doses can disrupt sleep. The method of consumption and individual health factors are important considerations, and consulting a healthcare provider is recommended before use.
Cannabis stocks surged after Donald Trump shared a video promoting CBD use for seniors and advocating for Medicare coverage, highlighting ongoing discussions about federal cannabis decriminalization and reclassification, with industry leaders optimistic about potential policy changes.
Cannabis stocks surged after Donald Trump highlighted potential benefits of hemp-derived CBD for senior healthcare, including possible Medicare coverage, leading to optimism about regulatory changes and boosting shares of companies like Tilray, Canopy Growth, and Cronos Group.
Shares of cannabis companies surged after President Trump endorsed the potential benefits of cannabidiol (CBD) for senior healthcare, signaling possible reclassification of marijuana which could ease regulations and boost industry growth.